CANNAPHARMARX, INC. Deferred Federal Income Tax Expense (Benefit)
CANNAPHARMARX, INC. (CPMD) reported Deferred Federal Income Tax Expense (Benefit) of $1.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-31
- CANNAPHARMARX, INC. deferred federal income tax expense (benefit) for fiscal 2025 was $1.25M, a 377.85% increase from fiscal 2024.
- CANNAPHARMARX, INC. deferred federal income tax expense (benefit) for fiscal 2024 was $261.59K.
- CANNAPHARMARX, INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$267.51K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $1.25M 10-K · filed 2026-03-31 |
| 2024-12-31 | $261.59K 10-K · filed 2026-03-31 |
| 2023-12-31 | -$267.51K 10-K · filed 2025-04-10 |